15 completed, 3 terminated, 2 unknown. 20 Phase 3, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 20 | Completed 15, Terminated 3, Unknown 2 |
| Phase 2 | 3 | Completed 2, Terminated 1 |
Follow rofecoxib: new trials by email Literature Review of rofecoxib trials Research Report on rofecoxib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Rofecoxib Efficacy and Safety Evaluation Trial in Hemophilic Arthropathy TRM-201 (Rofecoxib), Placebo - Hemophilic Arthropathy | Phase 3 | Terminated | Tremeau Pharmceuticals, Inc. | 2 | 2021-06-02 | 2022-10-27 |
| Selective COX-II Inhibitor as an Adjuvant Therapy in Patients With Resectable Advanced Stomach Cancer ( Histological Staging ≥ T2N1) - A Multi-Centre Prospective Randomised Controlled Trial Oral Vioxx (Rofecoxib) - Cancer of Stomach | Phase 3 | Unknown | Chinese University of Hong Kong | 214 | 2004-10-01 | 2005-11-17 |
| Selective COX-II Inhibitor as a Palliative Therapy in Patients With R1 or R2 Resection for Disseminated Stomach Cancer - A Multi-Centre Prospective Randomized Controlled Trial Vioxx (Rofecoxib) - Cancer of Stomach | Phase 3 | Unknown | Chinese University of Hong Kong | 206 | 2004-10-01 | 2005-12-09 |
| Coxib-inhibition of Duodenal Polyp Growth in FAP Rofecoxib, placebo - Duodenal Polyposis | Phase 2 / Phase 3 | Terminated | Oslo University Hospital | 38 | 2003-09-01 | 2011-07-06 |
| A Study of Two Approved Drugs in the Treatment of Post-Bunionectomy Surgery Pain (0966-234)(COMPLETED) MK0966, rofecoxib, Comparator: diclofenac sodium, placebo - Postoperative Pain | Phase 3 | Completed | Merck Sharp & Dohme LLC | 251 | 2003-09-01 | 2017-05-09 |
| A Study of Two Approved Drugs in Patients With Osteoarthritis (0966-219) MK0966, rofecoxib, Comparator: celecoxib, placebo - Osteoarthritis | Phase 3 | Completed | Merck Sharp & Dohme LLC | 395 | 2003-04-29 | 2017-05-09 |
| A Study to Evaluate Rofecoxib Versus Placebo and Diclofenac in Patients With Acute Painful Rotator Cuff Syndrome MK0966; rofecoxib, Comparator: diclofenac, placebo - Pain | Phase 3 | Terminated | Merck Sharp & Dohme LLC | 274 | 2003-04-01 | 2006-12-05 |
| A Study of Two Approved Drugs in Patients With Osteoarthritis (0966-220)(COMPLETED) MK0966, rofecoxib, Comparator: celecoxib, placebo - Osteoarthritis | Phase 3 | Completed | Merck Sharp & Dohme LLC | 413 | 2003-04-01 | 2017-05-09 |
| Treatment With MK0966 for the Prevention of Prostate Cancer (0966-201) rofecoxib, Comparator: placebo (unspecified) - Prostate Cancer | Phase 3 | Completed | Merck Sharp & Dohme LLC | 15000 | 2003-01-08 | 2017-05-09 |
| Study of Rofecoxib and Prolonged Constant Infusion of Gemcitabine in the Polychemotherapy Treatment of Advanced NSCLC gemcitabine, prolonged continuous infusion gemcitabine, cisplatin - Advanced Non-small Cell Lung Cancer | Phase 2 / Phase 3 | Completed | National Cancer Institute, Naples | 400 | 2003-01-01 | 2023-03-23 |
| A Study of Two Approved Drugs in the Treatment of Postoperative Dental Pain (0966-190)(COMPLETED) MK0966, rofecoxib, Comparator: valdecoxib, placebo - Postoperative Pain | Phase 3 | Completed | Merck Sharp & Dohme LLC | 125 | 2002-08-01 | 2017-05-09 |
| A Study of Two Approved Drugs in the Treatment of Postoperative Dental Pain (0966-183) MK0966, rofecoxib, Comparator: oxycodone with acetaminophen, placebo - Postoperative Pain | Phase 3 | Completed | Merck Sharp & Dohme LLC | 269 | 2002-06-01 | 2016-02-22 |
| A Study of Two Approved Drugs in the Treatment of Postoperative Dental Pain (0966-182) MK0966, rofecoxib, Comparator: oxycodone and acetaminophen - Postoperative Pain | Phase 3 | Completed | Merck Sharp & Dohme LLC | 271 | 2002-06-01 | 2015-11-25 |
| A Study of Two Approved Drugs in the Treatment of Postoperative Dental Pain (0966-181)(COMPLETED) MK0966, rofecoxib, Comparator: valdecoxib - Postoperative Pain | Phase 3 | Completed | Merck Sharp & Dohme LLC | 450 | 2002-05-01 | 2015-08-04 |
| Effect of Rofecoxib and a Narcotic Analgesic to Treat Pain Following Arthroscopic Surgery (0966-179)(COMPLETED) MK0966 / Duration of Treatment: 1 Days, Comparator: acetaminophen (+) hydrocodone bitartrate / Duration of Treatment: 1 Days, Comparator: placebo (unspecified) / Duration of Treatment: 1 Days - Pain, Postoperative Arthroscopy | Phase 3 | Completed | Merck Sharp & Dohme LLC | 420 | 2002-02-01 | 2017-02-02 |
| Rofecoxib After Surgery in Treating Patients With Stage II or Stage III Colorectal Cancer rofecoxib, adjuvant therapy - Colorectal Cancer | Phase 3 | Completed | Cancer Research Campaign Clinical Trials Centre | 2001-02-01 | 2013-08-02 | |
| Safety of Lumiracoxib in Patients With Osteoarthritis lumiracoxib, rofecoxib - Osteoarthritis | Phase 3 | Completed | Novartis | 309 | 2000-12-01 | 2008-03-18 |
| A Study to Evaluate the Effect of MK0966 (Rofecoxib) on the Recurrence of Colorectal Adenomas (0966-122) MK0966; Rofecoxib / Duration of Treatment: 156 weeks, Placebo/ Duration of Treatment: 156 weeks - Colorectal Adenoma | Phase 3 | Completed | Merck Sharp & Dohme LLC | 2586 | 1999-12-23 | 2017-05-09 |
| A Four-Week Study Comparing Acetaminophen Extended Release and Rofecoxib in the Treatment of Osteoarthritis of the Knee acetaminophen, Rofecoxib - Osteoarthritis of the Knee | Phase 3 | Completed | Johnson & Johnson Consumer and Personal Products Worldwide | 403 | 1999-10-01 | 2011-08-22 |
| A Multicenter Trial of Rofecoxib and Naproxen in Alzheimer's Disease (NSAID Study) Rofecoxib, Naproxen - Alzheimer Disease | Phase 2 / Phase 3 | Completed | National Institute on Aging (NIA) | 2009-12-11 |
Pain, Postoperative (5) · Osteoarthritis (3) · Pain (3) · Stomach Neoplasms (2) · Alzheimer Disease (1) · Arthralgia (1) · Colonic Neoplasms (1) · Colorectal Neoplasms (1) · Hemophilia A (1) · Osteoarthritis, Knee (1) · Prostatic Neoplasms (1) · Rectal Neoplasms (1)
Merck Sharp & Dohme LLC (11) · Chinese University of Hong Kong (2) · Cancer Research Campaign Clinical Trials Centre (1) · Johnson & Johnson Consumer and Personal Products Worldwide (1) · National Cancer Institute, Naples (1) · National Institute on Aging (NIA) (1) · Novartis (1) · Oslo University Hospital (1) · Tremeau Pharmceuticals, Inc. (1)
China (2) · Italy (2) · United States (2) · Australia (1) · Canada (1) · France (1) · Norway (1) · Poland (1) · Spain (1) · Turkey (Türkiye) (1) · Ukraine (1) · United Kingdom (1)
Enders K.W. Ng, MD (2) · Cesare Gridelli, M.D. (1) · David J. Kerr, MD, FRCP, DSc (1) · Edwin Kuffner, MD (1) · Francesco Perrone, M.D., Ph.D. (1) · Judith Boice, PhD (1) · Leon Thal, MD (1)
PMID 12783912, PMID 17513173, PMID 17652651, PMID 18778469, PMID 18922570, PMID 20837956, PMID 25624439, PMID 32797734